$RLFTF DD by rk on Yh0 - Todays Woodland Report :
Post# of 653
(Total Views: 271)
Posted On: 05/20/2021 4:19:19 PM
$RLFTF DD by rk on Yh0 - Todays Woodland Report : Shares of Big Rock Partners Acquisition (BRPA) surged on high volatility and has received a couple trade halts in early market trading.
Currently, BRPA is a special acquisition company or SPAC that announced a couple months ago its intended merger with molecule pharmaceutical company NeuroRx, the company excels at rapid development of already-known molecules to deliver lifesaving solutions in record time at minimum cost. The proposed business combination between the two companies, if approved by the stockholders of BRPA and NeuroRx, is currently expected to close in Q2 2021.
One molecule that the company is developing is Zyesami (or Aviptadil/RLF-100), created, developed and patented by Relief Therapeutics (RLFTF) for the treatment of COVID-19 related lung injury and acute respiratory failure.
To sum it all up, Zyesami’s clinical trials showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells.
Patients with Critical COVID-19 were seen to have a rapid clearing of classic pneumonitis findings on x-ray, accompanied by an improvement in blood oxygen and a 50% or greater average decrease in laboratory markers associated with COVID-19 inflammation.
Currently, BRPA is a special acquisition company or SPAC that announced a couple months ago its intended merger with molecule pharmaceutical company NeuroRx, the company excels at rapid development of already-known molecules to deliver lifesaving solutions in record time at minimum cost. The proposed business combination between the two companies, if approved by the stockholders of BRPA and NeuroRx, is currently expected to close in Q2 2021.
One molecule that the company is developing is Zyesami (or Aviptadil/RLF-100), created, developed and patented by Relief Therapeutics (RLFTF) for the treatment of COVID-19 related lung injury and acute respiratory failure.
To sum it all up, Zyesami’s clinical trials showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells.
Patients with Critical COVID-19 were seen to have a rapid clearing of classic pneumonitis findings on x-ray, accompanied by an improvement in blood oxygen and a 50% or greater average decrease in laboratory markers associated with COVID-19 inflammation.
(0)
(0)Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ
Scroll down for more posts ▼